17 results on '"Bendiske, Jennifer"'
Search Results
2. Lysosomal Dysfunction Produces Distinct Alterations in Synaptic α-Amino-3-Hydroxy-5-Methylisoxazolepropionic Acid and N-Methyl-D-Aspartate Receptor Currents in Hippocampus
3. Lysosomal Activation Is a Compensatory Response Against Protein Accumulation and Associated Synaptopathogenesis—An Approach for Slowing Alzheimer Disease?
4. The neuropathogenic contributions of lysosomal dysfunction
5. Intracellular Deposition, Microtubule Destabilization, and Transport Failure: An “Early” Pathogenic Cascade Leading to Synaptic Decline
6. Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
7. Survival Signaling and Selective Neuroprotection Through Glutamatergic Transmission
8. Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
9. Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.
10. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.
11. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.
12. Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)
13. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
14. Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592)
15. Lysosomal Dysfunction Produces Distinct Alterations in Synaptic {alpha}-Amino-3-Hydroxy-5-Methylisoxazolepropionic Acid and N-Methyl-D-Aspartate Receptor Currents in Hippocampus
16. Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis--an approach for slowing Alzheimer disease?
17. Intracellular deposition, microtubule destabilization, and transport failure: an "early" pathogenic cascade leading to synaptic decline.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.